Insider Selling: BioSyent (CVE:RX) Director Sells C$12,751.20 in Stock

BioSyent Inc. (CVE:RX) Director Stephen Edwin William Wilton sold 805 shares of the stock in a transaction dated Friday, August 28th. The shares were sold at an average price of C$15.84, for a total transaction of C$12,751.20. Following the completion of the transaction, the director directly owned 7,876 shares of the company’s stock, valued at approximately C$124,755.84. The trade was a 9.27% decrease in their position.

BioSyent Stock Performance

RX opened at C$15.75 on Monday. The stock has a 50-day moving average of C$14.77 and a 200 day moving average of C$14.73. The company has a current ratio of 2.07, a quick ratio of 6.91 and a debt-to-equity ratio of 6.85. BioSyent Inc. has a 12 month low of C$10.65 and a 12 month high of C$16.00. The firm has a market cap of C$178.10 million, a P/E ratio of 18.44 and a beta of 1.00.

BioSyent Company Profile

BioSyent Inc, together with its subsidiaries, acquires or licenses, develops, and sells pharmaceutical and other healthcare products in Canada and internationally. Its products include FeraMAX Pd Therapeutic 150 for the treatment of iron deficiency anemia; FeraMAX Pd Maintenance 45, a chewable supplement for the prevention of iron deficiency anemia; and FeraMAX Pd Powder 15, a powder form product used for preventing iron deficiency and iron deficiency anemia. It offers Tibella, a hormone replacement therapy consisting of tibolone; Inofolic, a natural health product to address polycystic ovarian syndrome symptoms; RepaGyn, a vaginal suppository for the healing of the vaginal mucosa, as well as for the treatment of vaginal dryness caused by aging, menopause, stress, and chemotherapy; and Gelclair, a gel formulated to aid the pain or oral mucositis.